This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kutscha-Lissberg, F.
Right arrow Articles by Köller, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kutscha-Lissberg, F.
Right arrow Articles by Köller, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2003, p. 3964-3966, Vol. 47, No. 12
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.12.3964-3966.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Linezolid Penetration into Bone and Joint Tissues Infected with Methicillin-Resistant Staphylococci

Friedrich Kutscha-Lissberg,* Ute Hebler, Gert Muhr, and Manfred Köller

Department of Surgery-Trauma Center, BG Kliniken Bergmannsheil-Universitätsklinik, Ruhr University, Bochum, Germany

Received 21 January 2003/ Returned for modification 13 June 2003/ Accepted 30 August 2003

Penetration of linezolid into bone and joint tissues was studied by high-performance liquid chromatography in 13 patients suffering from implant-associated infections with methicillin-resistant staphylococci. Mean concentrations of linezolid in infected tissues were greater than 10 mg/liter in a sampling time range of 35 to 124 min after administration of the preoperative dose, except in bone specimens, where they reached 3.9 ± 2.0 mg/liter.

* Corresponding author. Mailing address: BG Kliniken Bergmannsheil-Universitätsklinik, Chirurgische Klinik, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany. Phone: 0049-234-3026500. Fax: 0049-234-3026542. E-mail: Friedrich.Kutscha-Lissberg{at}ruhr-uni-bochum.de.

Antimicrobial Agents and Chemotherapy, December 2003, p. 3964-3966, Vol. 47, No. 12
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.12.3964-3966.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Bayston, R., Nuradeen, B., Ashraf, W., Freeman, B. J. C. (2007). Antibiotics for the eradication of Propionibacterium acnes biofilms in surgical infection. J Antimicrob Chemother 60: 1298-1301 [Abstract] [Full Text]  
  • Stein, G. E., Schooley, S., Peloquin, C. A., Missavage, A., Havlichek, D. H. (2007). Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother 60: 819-823 [Abstract] [Full Text]  
  • Buerger, C., Plock, N., Dehghanyar, P., Joukhadar, C., Kloft, C. (2006). Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.. Antimicrob. Agents Chemother. 50: 2455-2463 [Abstract] [Full Text]  
  • De Beeck, V. O., Dhif, N., Philipp, J., De Bels, D. (2006). Comment on: Linezolid use in sepsis due to methicillin-susceptible Staphylococcus aureus. J Antimicrob Chemother 57: 577-577 [Full Text]  
  • De Gascun, C., Rajan, L., O'Neill, E., Smyth, E. G. (2006). Linezolid use in sepsis due to methicillin-susceptible Staphylococcus aureus. J Antimicrob Chemother 57: 150-151 [Full Text]  
  • Weigelt, J., Itani, K., Stevens, D., Lau, W., Dryden, M., Knirsch, C., the Linezolid CSSTI Study Group, (2005). Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections. Antimicrob. Agents Chemother. 49: 2260-2266 [Abstract] [Full Text]  
  • De Bels, D., Garcia-Filoso, A., Jeanmaire, M., Preseau, T., Miendje, Y., Devriendt, J. (2005). Successful treatment with linezolid of septic shock secondary to methicillin-resistant Staphylococcus aureus arthritis. J Antimicrob Chemother 55: 812-813 [Full Text]  
  • Schriever, C., Zeitz-Colaizzi, L., Quinn, A., Schriever, A. E., Cannon, J. P. (2005). Considerations for the Management of Gram-Positive Pathogens in the Intensive Care Unit. Journal of Pharmacy Practice 18: 100-108 [Abstract]  
  • Bassetti, M., Vitale, F., Melica, G., Righi, E., Di Biagio, A., Molfetta, L., Pipino, F., Cruciani, M., Bassetti, D. (2005). Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother 55: 387-390 [Abstract] [Full Text]  
  • Stein, G. E, Schooley, S. L, Peloquin, C. A, Kak, V., Havlichek, D. H, Citron, D. M, Tyrrell, K. L, Goldstein, E. J. (2005). Pharmacokinetics and Pharmacodynamics of Linezolid in Obese Patients with Cellulitis. The Annals of Pharmacotherapy 39: 427-432 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»